About Evotec SE
https://www.evotec.comEvotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health.
CEO
Christian Wojczewski
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2021-10-20 | Forward | 4:1 |
| 2008-05-05 | Forward | 10000:5271 |
ETFs Holding This Stock
Summary
Showing Top 3 of 61
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
MUBADALA INVESTMENT CO PJSC
Shares:4.6M
Value:$17.01M
WELLINGTON MANAGEMENT GROUP LLP
Shares:1.43M
Value:$5.29M
BLACKROCK, INC.
Shares:1.3M
Value:$4.81M
Summary
Showing Top 3 of 42
About Evotec SE
https://www.evotec.comEvotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $163.89M ▼ | $44.44M ▲ | $-43.09M ▲ | -26.29% ▼ | $-0.12 | $-17.64M ▲ |
| Q2-2025 | $171.24M ▼ | $36.37M ▼ | $-43.48M ▼ | -25.39% ▼ | $-0.12 ▼ | $-37.42M ▼ |
| Q1-2025 | $199.98M ▼ | $47.23M ▲ | $-31.58M ▲ | -15.79% ▲ | $-0.09 ▲ | $-27.44M ▼ |
| Q4-2024 | $221.23M ▲ | $39.31M ▼ | $-40.84M ▼ | -18.46% ▲ | $-0.11 | $-6M ▲ |
| Q3-2024 | $184.89M | $44.78M | $-39.63M | -21.44% | $-0.11 | $-45.01M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $237.27M ▼ | $1.77B ▼ | $972.56M ▼ | $800.14M ▼ |
| Q2-2025 | $408.5M ▲ | $2.12B ▲ | $1.13B ▲ | $992.83M ▲ |
| Q1-2025 | $401.23M ▲ | $2.1B ▲ | $1.12B ▲ | $985.29M ▲ |
| Q4-2024 | $396.8M ▲ | $1.91B ▼ | $959.98M ▼ | $952.52M ▼ |
| Q3-2024 | $338.47M | $2.22B | $1.14B | $1.08B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-43.09M ▲ | $-67.56M ▼ | $-7.24M ▲ | $-12.13M ▲ | $-88.55M ▼ | $-87.77M ▼ |
| Q2-2025 | $-43.48M ▼ | $26.56M ▲ | $-21.94M ▼ | $-14.7M ▼ | $-17.55M ▲ | $2.7M ▲ |
| Q1-2025 | $-31.58M ▲ | $-31.81M ▼ | $-21.61M ▼ | $35.43M ▲ | $-21.01M ▼ | $-53.65M ▼ |
| Q4-2024 | $-40.84M ▼ | $74.22M ▲ | $16.92M ▲ | $-29.33M ▼ | $75.09M ▲ | $49.14M ▲ |
| Q3-2024 | $-39.63M | $42.6M | $-25.92M | $-7.18M | $9.41M | $14.26M |
CEO
Christian Wojczewski
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2021-10-20 | Forward | 4:1 |
| 2008-05-05 | Forward | 10000:5271 |
ETFs Holding This Stock
Summary
Showing Top 3 of 61
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
MUBADALA INVESTMENT CO PJSC
Shares:4.6M
Value:$17.01M
WELLINGTON MANAGEMENT GROUP LLP
Shares:1.43M
Value:$5.29M
BLACKROCK, INC.
Shares:1.3M
Value:$4.81M
Summary
Showing Top 3 of 42